Latest news with #TarsusPharmaceuticals
Yahoo
29-05-2025
- Business
- Yahoo
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CT Jefferies Global Healthcare Conference on Wednesday, June 4th, at 12:45 p.m. PT / 3:45 p.m. ET Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, at 10:20 a.m. PT / 1:20 p.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodexblepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea, and TP-05 as an oral tablet for the potential prevention of Lyme disease. Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801AKemp@ Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) has been beaten down lately with too much selling pressure. While the stock has lost 15.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30. Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal. So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound. However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision. The RSI reading of 29.83 for TARS is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand. This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering TARS in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 19.5% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term. Moreover, TARS currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tarsus Pharmaceuticals, Inc. (TARS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
05-05-2025
- Business
- Yahoo
Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts
We recently published a list of . In this article, we are going to take a look at where Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) stands against other best breakout stocks to buy according to analysts. Stock markets have been on edge in response to the US President's aggressive trade war that has resulted in trade tariffs aimed at settling the trade deficit. Likewise, stocks remain on edge, with the US president ramping up attacks against the Federal Reserve Chair Jerome Powell raising serious concerns about the central bank's independence. Trump has been on Powell's neck over what he terms as laxity in cutting interest rates at a time when major central banks led by the European Central Bank and Bank of Canada have cut significantly. In posts on his social network Trust Social, Trump has always insisted that the US economy would slow unless Powell, who he has always deemed as 'Mr. Too Late, a major loser,' cut rates. The remarks come against the backdrop of major indices pulling back significantly from record highs as stocks remain under pressure across various sectors. The S&P 500 has already closed on the negative for the 3rd straight month, waiting to see if the selloff will persist. The last time the index closed negative for 4 straight months was in 2011. While a negative, the sell-off has presented unique investment opportunities as valuations have pulled back significantly from historical highs. Likewise, the pullback has given rise to solid breakout plays as the selloff dust slowly settles. Nearly two-thirds of the S&P 500 stocks have posted first-quarter 2025 results that have topped estimates. Strong quarterly results from some of the big tech giants are helping alleviate concerns about the potential impact of Trump's tariffs. Likewise, the solid earnings have once again eased concerns that the artificial intelligence progress has slowed amid economic turmoil triggered by the trade war. 'Few stocks are truly immune to Trump tariffs [and] trade war, but AI is a lot less impacted than investors currently believe,' said Jed Ellerbroek, portfolio manager at Argent Capital Management. 'We're early in a very steep growth curve right now, and that goes for AI infrastructure.' China signaling it is evaluating the possibility of starting trade negotiations with the US is a positive for the markets under pressure. The remarks come at a time when the Trump administration is increasingly targeting quick wins with major trading partners. The prospects of a trade agreement between the US and China should be a catalyst to trigger a significant bounce back after months of deep sell-offs. To compile a list of 11 Best Breakout Stocks to Buy According to Analysts, we analyzed the holdings of the IBD Breakout Opportunities ETF. We then settled on 11 companies backed by solid underlying fundamentals and well poised to breakout, according to analysts, once the sell off dust in the equity markets settles. Finally, we ranked these stocks in ascending order based on analysts' upside potential (as of May 2). At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (). A doctor examining a patient's eyes via microscope, while noting down their diagnosis. Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is a biopharmaceutical company that develops and commercializes therapeutics, primarily emphasizing eye care. Their lead product, XDEMVY, is an FDA-approved treatment for Demodex blepharitis. It also explores TP-04 for ocular rosacea and TP-05 for Lyme disease and malaria prevention. While the stock is down by about 8% year-to-date, it is one of the best breakout stocks to buy, according to analysts. Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) long-term prospects hinge on XDEMVY, an eye treatment that is gaining significant traction among Eye Care Professionals (ECPs). Over 11,000 ECPs have prescribed the treatment, affirming broad market adoption and penetration, expected to fuel long-term revenue growth. The treatment option has been the catalyst behind the company's sales surging by over 900% over the past 12 months. In the first quarter of 2025, revenues nearly tripled to $78.34 million compared to $27.61 million for the same quarter last year. While the focus has been XDEMVY, Tarsus is also looking to diversify its revenue base with increased emphasis on Meibomian Gland Dysfunction (MGD) treatments. Overall, TARS ranks 11th on our list of best breakout stocks to buy according to analysts. While we acknowledge the potential of TARS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TARS but that trades at less than 5 times its earnings check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
01-05-2025
- Business
- Yahoo
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the first quarter ended March 31, 2025. 'Tarsus has entered 2025 with incredible momentum, driven by strong execution of our category-creating strategic blueprint for success and a focused commitment to leadership in eye care. The XDEMVY launch is continuing to exceed our expectations and is on track to potentially become one of the best-selling anterior segment medicines,' said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. 'Building on a foundation of strong commercial performance and the success of our recent equity offering, we believe we are well positioned to accelerate the growth of XDEMVY, create another new category in Ocular Rosacea and continue to advance our pipeline.' Recent Business and Clinical Highlights XDEMVY is on track to potentially be one of the fastest growing and best-selling anterior segment medicines. In the first quarter, the Company: Generated $78.3 million in XDEMVY net product sales, an increase of 217% year over year and 18% over Q4 2024. Dispensed approximately 72,000 bottles of XDEMVY to patients, an increase of 23% over Q4 2024. Broad commercial, Medicare and Medicaid reimbursement of XDEMVY now extends to more than 90% of covered lives. Recognized a gross-to-net discount of approximately 47%. Substantially increased the depth of prescribing among our target Eye Care Professionals (ECPs). At the end of Q1 2025, the number of ECPs writing more than one prescription per week increased by nearly 110% compared to Q3 2024. Direct-To-Consumer (DTC) advertising drove a 140% increase in the average weekly website visits in March 2025 compared to December 2024. Ongoing investment expected to increase alongside leading indicators of utilization. Presented new data showing the global prevalence and real-world patient burden of Demodex blepharitis (DB). The Elara study showed the high prevalence and significant impact of DB in Japan, consistent with the U.S. Results of the Orion registry showed XDEMVY-treated patients experienced meaningful improvements in some of the most impactful symptoms of disease, including fluctuating vision, redness, itchy eyelids, burning or stinging, dryness and crusted eyes. The combined data from the Ersa and Rhea studies in DB patients with Meibomian Gland Disease (MGD) showed statistically significant and clinically meaningful improvements of the meibomian glands, with at least three times more glands secreting normal or clear liquid in XDEMVY-treated patients compared to vehicle at day 43. Strengthened financial position with a $134.8 million upsized public equity offering which will continue to fund the launch of XDEMVY and ongoing pipeline investment. Continued to advance a robust pipeline with multiple catalysts expected in 2025. On-track to initiate a Phase 2 study of TP-04 (lotilaner ophthalmic gel) for Ocular Rosacea, a highly prevalent and underserved eye disease with no FDA-approved therapy, in H2 2025. Anticipated to meet with regulatory authorities in Japan in H2 2025 to help determine a regulatory path forward for XDEMVY in Japan. On-track for potential European regulatory approval in 2027 of a preservative-free formulation of XDEMVY. On-track to initiate a Phase 2 study of TP-05 (an investigational oral tablet) for the potential prevention of Lyme disease in 2026. First Quarter 2025 Financial Results Product sales, net: were $78.3 million compared to $24.7 million for the same period in 2024, driven by approximately 72,000 bottles of XDEMVY delivered to patients compared to approximately 26,000 bottles delivered in the prior year period. Cost of sales: were $5.2 million compared to $1.7 million for the same period in 2024, due to manufacturing costs incurred after the approval of XDEMVY, the royalty we pay on net product sales, and the amortization of the milestones paid to our licensor, which is being amortized over its remaining useful life of 8.4 years. Research and development (R&D) expenses: were $14.4 million compared to $12.1 million for the same period in 2024. The increase was primarily due to $0.5 million of increased TP-04 program expenses, $0.9 million of increased payroll and personnel-related costs, $0.9 million of increased early-stage programs, and $0.3 million of increased other indirect expenses. These increases were partially offset by $0.4 million of decreased TP-03 program expenses. Total R&D non-cash stock compensation expense was $1.5 million, which was consistent with $1.5 million in the same period in 2024. Selling, general and administrative (SG&A) expenses: were $85.0 million compared to $51.6 million for the same period in 2024. The increase was due primarily to $9.6 million of increased payroll and personnel-related costs (including non-cash stock-based compensation), and $25.6 million of increased commercial and marketing costs, including direct-to-consumer advertising costs, as we continued our commercial expansion of XDEMVY. These increases were partially offset by $1.9 million of decreased information technology applications, legal, professional and other corporate expenses. Total SG&A non-cash stock compensation expense was $5.3 million, compared with $3.9 million in the same period in 2024. Net loss: was $25.1 million, compared to $35.7 million for the same period in 2024. Basic and diluted net loss per share for the quarter ended March 31, 2025 was $(0.64), compared with $(1.01) for the same period in 2024. Cash position: As of March 31, 2025, cash, cash equivalents and marketable securities were $407.9 million. Conference Call and WebcastTarsus will host a conference call and webcast to discuss its first quarter 2025 financial results and business highlights today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. ET. A live webcast will be available on the events section of the Tarsus website. A recorded version of the call will be available on the website shortly after the completion of the call and will be archived there for at least 90 days. About XDEMVY® XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials collectively involving more than 800 patients. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis. XDEMVY Indication and Important Safety Information INDICATIONS AND USAGEXDEMVY is indicated for the treatment of Demodex blepharitis. Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis. For additional information, please see full prescribing information available at: About TP-03TP-03 (lotilaner ophthalmic solution) 0.25% is a novel therapeutic designed to treat Demodex blepharitis by targeting and eradicating the root cause of disease – Demodex mite infestation. It was approved by the FDA in 2023 under the brand name XDEMVY® for the treatment of Demodex blepharitis. Lotilaner is a well-characterized anti-parasitic agent that paralyzes and eradicates Demodex mites by selectively inhibiting parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. It is a highly lipophilic molecule, which may promote its uptake in the oily sebum of the eye lash follicles where the mites reside. About TP-04TP-04 is an investigational aqueous gel formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills mites by selectively inhibiting parasite-specific GABA-Cl channels. Tarsus is studying TP-04 for the treatment of Ocular Rosacea (OR). About TP-05TP-05 is an investigational oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-Cl channels. TP-05 is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks to potentially prevent Lyme disease transmission. About Tarsus Pharmaceuticals, Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2. Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including market size, acceptance, demand, prescription fill rate and adoption rate for XDEMVY; our ability to successfully implement and continue our new direct-to-consumer campaign; our ability to achieve and maintain distribution and patient access for XDEMVY and timing and breadth of payer coverage; our ability to continue to educate the market about Demodex blepharitis; our ability to initiate planned clinical studies; anticipated regulatory and development milestones including potential Europe and Japan regulatory pathways and approval for XDEMVY; the results of our clinical studies; the test results of our pipeline formulations; our ability to continue investing in our business, and the quotations of Tarsus' management. The words, without limitation, 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would,' or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus is heavily dependent on the successful commercialization of its lead product, XDEMVY for the treatment of Demodex blepharitis and the development and regulatory approval and commercialization of its current and future product candidates; Tarsus' ability to obtain and maintain regulatory approval for and successfully commercialize its products, including XDEMVY for the treatment of Demodex blepharitis, and its product candidates to meet existing and future regulatory standards; Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future; Tarsus' capital requirements are difficult to predict and may change; Tarsus may need to obtain additional funding to achieve its goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force Tarsus to delay, reduce, or eliminate its product development programs, commercialization efforts or other operations; Tarsus may not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis and other diseases targeted by XDEMVY or our product candidates; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus expects to expand its development, regulatory, operational, sales, and marketing capabilities and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for XDEMVY and Tarsus' product candidates, particularly TP-04 for the treatment of Ocular Rosacea, as well as TP-05 for the prevention of Lyme disease, have not been established with precision and may be smaller than estimated; the results of Tarsus' earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus' planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects; if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus' competitors could develop and commercialize products similar or identical to Tarsus' products; and if Tarsus is unable to access capital (including but not limited to cash, cash equivalents, and credit facilities) and/or loses capital, as a result of potential failure of any financial institutions that Tarsus does business with directly or indirectly. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statements and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus' Form 10-K for the year ended December 31, 2024 filed on February 25, 2025 and the most recent Form 10-Q quarterly filing filed with the SEC on May 1, 2025, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this earnings release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Media Contact: Adrienne Kemp Sr. Director, Corporate Communications (949) 922-0801 akemp@ Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223 DNakasone@ TARSUS PHARMACEUTICALS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (unaudited) Three Months EndedMarch 31, 2025 2024 Revenues: Product sales, net $ 78,335 $ 24,720 License fees and collaboration revenue — 2,894 Total revenues 78,335 27,614 Operating expenses: Cost of sales 5,211 1,654 Research and development 14,409 12,066 Selling, general and administrative 84,995 51,578 Total operating expenses 104,615 65,298 Loss from operations before other income (expense) (26,280 ) (37,684 ) Other income (expense): Interest income 3,454 3,117 Interest expense (2,213 ) (983 ) Other income (expense), net (81 ) (181 ) Total other income (expense), net 1,160 1,953 Net loss $ (25,120 ) $ (35,731 ) Unrealized gain (loss) on marketable securities and cash equivalents (94 ) (61 ) Comprehensive loss $ (25,214 ) $ (35,792 ) Net loss per share, basic and diluted $ (0.64 ) $ (1.01 ) Weighted-average shares outstanding, basic and diluted 39,345,359 35,300,655 TARSUS PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS (In thousands, except share and par value amounts) March 31, 2025 December 31, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 175,787 $ 94,819 Marketable securities 232,129 196,557 Accounts receivable, net 62,426 46,760 Inventory 2,705 2,620 Other receivables 1,727 1,299 Prepaid expenses 5,999 14,650 Total current assets 480,773 356,705 Restricted cash, non-current 2,563 2,562 Inventory, non-current 2,532 2,533 Property and equipment, net 2,787 2,314 Intangible assets, net 8,086 8,326 Operating lease right-of-use assets 393 552 Long-term investments 3,000 3,000 Other assets 616 999 Total assets $ 500,750 $ 376,991 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and other accrued liabilities $ 76,375 $ 64,789 Accrued payroll and benefits 9,933 15,823 Total current liabilities 86,308 80,612 Long-term debt, net 71,984 71,845 Total liabilities 158,292 152,457 Commitments and contingencies Stockholders' equity: Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding — — Common stock, $0.0001 par value; 200,000,000 shares authorized; 41,995,537 shares issued and outstanding at March 31, 2025 (unaudited); 38,349,826 shares issued and outstanding at December 31, 2024 6 6 Additional paid-in capital 727,697 584,559 Accumulated other comprehensive income (loss) 85 179 Accumulated deficit (385,330 ) (360,210 ) Total stockholders' equity 342,458 224,534 Total liabilities and stockholders' equity $ 500,750 $ 376,991 Sign in to access your portfolio
Globe and Mail
10-03-2025
- Business
- Globe and Mail
Rosacea Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight
"Rosacea Treatment Market" Rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others. (Albany, USA) DelveInsight's ' Rosacea Market Insights, Epidemiology, and Market Forecast-2034 ' report offers an in-depth understanding of Rosacea, including historical and forecasted epidemiology, as well as Rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. The latest healthcare forecast report delivers a comprehensive analysis of Rosacea, offering critical insights into prevalence, revenue trends, and evolving Rosacea treatment options. The report discusses key statistics, including current and projected market sizes, while also delving into Rosacea symptoms and their impact on patients' quality of life. It evaluates the progress and effectiveness of emerging therapies for Rosacea alongside an in-depth examination of the clinical trial landscape. This includes a detailed review of ongoing and upcoming studies that are set to shape the future of Rosacea treatment. With its rich data and forward-looking insights, this report serves as an indispensable resource for understanding market dynamics and advancements in the field of Rosacea. Some of the key insights of Rosacea Market Report: The rosacea market size is expected to experience significant growth during the forecast period (2024–2034). This growth is a direct consequence of various market-driving factors such as improving access to diagnosis and treatment, increased awareness and research, advancements in treatment options, and increasing prevalence of rosacea. Emerging therapies for rosacea include AIV001, TP-04, B244, and others. Key rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others. In the US, the prevalence of rosacea is increasing, with around 16 million Americans affected, according to the American Academy of Dermatology. In the UK, rosacea affects approximately 2 per 1,000 persons, with prevalence rates ranging from 0.10% to 22%. In Germany, the prevalence of rosacea was around 12%, with erythematotelangiectatic (ETR) and papulopustular (PPR) subtypes accounting for 9% and 3%, respectively. About 18% of diagnosed cases were in individuals aged 18-30 years. Rosacea is more common in females, with nearly 90% of cases in women compared to 15% in men. The most common subtypes were erythematotelangiectatic (60%), papulopustular (30%), phytates (20%), and ocular (40%). The rosacea treatment market is currently led by EPSOLAY, a product by Sol-Gel Technologies and Galderma, which is expected to expand in the coming years. On November 5, 2024, the FDA approved minocycline hydrochloride extended-release capsules (DFD-29, Emrosi) for treating inflammatory lesions caused by rosacea in adults. This approval followed positive Phase 3 trial results. Rosacea Overview: Rosacea is a chronic skin condition characterized by facial erythema (redness) that affects around 1 in 10 people worldwide. Rosacea symptoms vary widely, with some individuals experiencing persistent redness, visible blood vessels, and swollen, red bumps that resemble acne. The condition can be categorized into four types: erythematotelangiectatic rosacea, papulopustular rosacea (PPR), phymatous rosacea, and ocular rosacea. Many patients exhibit symptoms of more than one type, making diagnosis and treatment more complex. Papulopustular rosacea, also known as inflammatory rosacea or type-2 rosacea, is commonly mistaken for acne due to the presence of 'whitehead' pustules and red, swollen bumps, particularly on the cheeks, chin, and forehead. This subtype of rosacea often flares up for weeks to months before subsiding temporarily. While the exact causes remain unclear, researchers suggest that genetic predisposition, immune responses to Bacillus oleronius and H. pylori infections, overproduction of cathelicidin protein, or Demodex mites living on the skin may play a role in its development. The diagnosis of rosacea is largely based on patient history and physical examination. However, its symptoms can be confused with other skin conditions such as adult acne vulgaris, photodermatitis, seborrheic dermatitis, or contact dermatitis. This overlap of rosacea symptoms highlights the need for careful evaluation to ensure accurate diagnosis and treatment. The therapeutic landscape of rosacea includes various drug classes used to treat rosacea, with treatments tailored based on the severity and subtype of the condition. The primary options include topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids. For moderate cases of papulopustular rosacea, combination therapy with oral tetracyclines and topical agents is the first-line choice. Maintenance therapy often involves topical agents like metronidazole. Among topical treatments, retinoids such as tretinoin, tazarotene, and adapalene are commonly prescribed to reduce erythema, papules, pustules, and telangiectasia. Tretinoin, one of the most affordable and widely used topical retinoids, is often the drug of choice for treating rosacea symptoms. Topical antibiotics, including metronidazole, clindamycin, erythromycin, azelaic acid, benzoyl peroxide, and sulfacetamide, are also applied to the skin to combat surface bacteria and reduce inflammation. Among the new drugs for rosacea, EPSOLAY is the only US FDA-approved topical treatment for rosacea, highlighting the growing focus on targeted therapies to address unmet needs in this space. With ongoing advancements, researchers continue to explore innovative drugs to treat rosacea, offering hope for improved management strategies and better quality of life for patients. Rosacea Epidemiology: The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. The Rosacea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total prevalent cases of rosacea Diagnosed prevalent cases of rosacea Type-specific diagnosed prevalent cases of rosacea Treated cases of rosacea Download the report to understand which factors are driving Rosacea epidemiology trends @ Rosacea Epidemiology Forecast Rosacea Drugs Uptake and Pipeline Development Activities: The drug uptake section examines the adoption rates of newly launched and upcoming Rosacea drugs over the study period. It analyzes the uptake of these treatments, evaluating how patients adopt these therapies and the sales performance of each drug. This section offers a comprehensive look at the factors influencing the acceptance and success of Rosacea treatments in the market. In addition, the therapeutics assessment section highlights the Rosacea drugs that have experienced the fastest uptake. It delves into the key drivers behind their widespread use and provides a market share comparison among these drugs. This section helps identify which therapies are gaining traction and the reasons behind their rapid adoption. The report further explores the Rosacea pipeline, providing insights into therapeutic candidates at different stages of development. It identifies the key companies involved in creating targeted Rosacea treatments. The report also covers recent developments in the field, including collaborations, mergers, acquisitions, licensing agreements, and other significant updates on emerging therapies for Rosacea. Rosacea Market Outlook: The Rosacea market is poised for significant changes and growth in the coming years, driven by ongoing research and development efforts to address unmet medical needs. Current treatment options for rosacea, particularly for papulopustular rosacea, include approved and off-label therapies belonging to therapeutic categories, such as topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids. Topical antibiotics, the most commonly prescribed class of rosacea for all sexes and age groups, include metronidazole, clindamycin, erythromycin, and azelaic acid, with metronidazole leading in prescription volume. Oral TCAs like tetracycline, minocycline, and doxycycline (Oracea) are effective anti-inflammatory agents, with tetracycline being the most prescribed, followed by minocycline and doxycycline. While oral retinoids, such as isotretinoin, are often used as an off-label therapy, studies suggest that low-dose isotretinoin may offer better outcomes compared to doxycycline in some instances. Despite the availability of these therapies, there remains a significant need for novel and more effective treatments to manage rosacea symptoms and improve patient outcomes. Encouragingly, many companies are developing innovative drugs to meet these unmet needs, which is expected to drive market growth. According to DelveInsight, the rosacea market in the 7MM (US, EU5, and Japan) is projected to experience substantial growth during the study period of 2020–2034, as advancements in research and therapeutic innovation continue to shape the market landscape. To learn more about Rosacea therapies and Compsnies working in the treatment market, visit @ Rosacea Medication and Pipeline Rosacea Market Drivers: The increasing prevalence of rosacea, driven by factors like environmental changes and lifestyle, is pushing the demand for treatments. Ongoing research and introducing new, more effective medications are encouraging growth in the rosacea market. Rosacea Market Barriers: The absence of a permanent cure for rosacea can lead to long-term patient frustration, affecting market confidence. The stigma surrounding visible skin conditions may discourage people from seeking treatment, limiting market potential. Scope of the Rosacea Market Report: Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Rosacea Companies: Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others. Key Rosacea Therapies: AIV001, TP-04, B244, and others. Rosacea Therapeutic Assessment: Rosacea currently marketed, and Rosacea emerging therapies Rosacea Market Dynamics: Rosacea market drivers and Rosacea market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Rosacea Unmet Needs, KOL's views, Analyst's views, Rosacea Market Access and Reimbursement To learn more about Rosacea companies working in the treatment market, visit @ Rosacea Clinical Trials and Therapeutic Assessment Table of Contents: 1. Rosacea Market Report Introduction 2. Executive Summary for Rosacea 3. SWOT analysis of Rosacea 4. Rosacea Patient Share (%) Overview at a Glance 5. Rosacea Market Overview at a Glance 6. Rosacea Disease Background and Overview 7. Rosacea Epidemiology and Patient Population 8. Country-Specific Patient Population of Rosacea 9. Rosacea Current Treatment and Medical Practices 10. Rosacea Unmet Needs 11. Rosacea Emerging Therapies 12. Rosacea Market Outlook 13. Country-Wise Rosacea Market Analysis (2020–2034) 14. Rosacea Market Access and Reimbursement of Therapies 15. Rosacea Market Drivers 16. Rosacea Market Barriers 17. Rosacea Appendix 18. Rosacea Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight: DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
